On November 21, 2018, the U.S. Food and Drug Administration (FDA) approved glasdegib (Daurismo) in combination with low-dose cytarabine (LDAC), for newly diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy.
Approval was based on a multicenter, open-label, randomized study (BRIGHT AML 1003, NCT01546038) that included 115 patients with newly diagnosed AML who met at least one of the following criteria: (a) aged 75 years or older, (b) severe cardiac disease, (c) baseline Eastern Cooperative Oncology Group performance status of 2, or (d) baseline serum creatinine > 1.3 mg/dL. Patients were randomized 2:1 to receive glasdegib, 100 mg daily, with LDAC 20 mg subcutaneously twice daily on days 1–10 of a 28-day cycle (n = 77) or LDAC alone (n = 38) in 28-day cycles until disease progression or unacceptable toxicity.
Efficacy was established based on an improvement in overall survival (date of randomization to death from any cause). With a median follow-up of 20 months, median survival was 8.3 months (95% CI = 4.4, 12.2) for the glasdegib + LDAC arm and 4.3 months (95% CI = 1.9, 5.7) for the LDAC alone arm and HR = 0.46 (95% CI = 0.30, 0.71; p = 0.0002).
The most common adverse reactions occurring in ≥ 20% of patients were anemia, fatigue, hemorrhage, febrile neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash.
The recommended glasdegib dose is 100 mg orally, once daily. Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.
FDA granted this application priority review and orphan product designation. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions—Drugs and Biologics.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 800-FDA-1088.
In collaboration with the FDA and as a service to our members, ONS provides updates on recent FDA approvals and other important FDA actions (e.g., updated safety information, new prescribing information) pertaining to therapies for patients with cancer. This allows the agency to inform oncologists and professionals in oncology-related fields in a timely manner. Included in the FDA updates is a link to the product label or to other sites for additional relevant clinical information. In supplying this information, ONS does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described.